Deka Bank Deutsche Girozentrale Puma Biotechnology, Inc. Transaction History

Deka Bank Deutsche Girozentrale

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 22, 2021	SELL	$6.63 - $9.39 $53,040 - $75,120	-8,000 Closed	0 $0
Q3 2020 Oct 29, 2020	BUY	$9.5 - $11.14 $76,000 - $89,120	8,000 New	8,000 $78,000
Q1 2020 May 14, 2020	SELL	$6.28 - $14.57 $32,392 - $75,152	-5,158 Closed	0 $0
Q4 2019 Feb 04, 2020	SELL	$6.5 - $10.73 $55,250 - $91,205	-8,500 Reduced 62.23%	5,158 $44,000
Q3 2019 Nov 14, 2019	SELL	$8.75 - $12.85 $74,375 - $109,225	-8,500 Reduced 38.36%	13,658 $152,000
Q2 2019 Aug 01, 2019	BUY	$12.3 - $35.76 $143,393 - $416,890	11,658 Added 111.03%	22,158 $282,000
Q1 2019 May 10, 2019	BUY	$20.77 - $42.37 $41,540 - $84,740	2,000 Added 23.53%	10,500 $461,000
Q4 2018 Feb 12, 2019	SELL	$20.07 - $46.7 $40,140 - $93,400	-2,000 Reduced 19.05%	8,500 $182,000
Q3 2018 Nov 09, 2018	SELL	$41.2 - $59.85 $12,360 - $17,955	-300 Reduced 2.78%	10,500 $0
Q2 2018 Aug 14, 2018	SELL	$48.3 - $68.25 $48,300 - $68,250	-1,000 Reduced 8.47%	10,800 $609,000
Q1 2018 May 03, 2018	BUY	$59.7 - $99.25 $704,460 - $1.17 Million	11,800 New	11,800 $779,000

102

29.1M

60.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $132M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.